142 related articles for article (PubMed ID: 8980778)
1. Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis.
Araujo FG; Hunter CA; Remington JS
Antimicrob Agents Chemother; 1997 Jan; 41(1):188-90. PubMed ID: 8980778
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis.
Djurković-Djaković O; Nikolić T; Robert-Gangneux F; Bobić B; Nikolić A
Antimicrob Agents Chemother; 1999 Sep; 43(9):2240-4. PubMed ID: 10471572
[TBL] [Abstract][Full Text] [Related]
3. Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
Araujo FG; Khan AA; Bryskier A; Remington JS
J Antimicrob Chemother; 1998 Nov; 42(5):665-7. PubMed ID: 9848454
[TBL] [Abstract][Full Text] [Related]
4. [Effects of atovaquone and astragalus combination on the treatment and IL-2, IL-12, IFN-γ levels on mouse models of acute toxoplasmosis].
Sönmez N; Büyükbaba Boral O; Kaşali K; Tekeli F
Mikrobiyol Bul; 2014 Oct; 48(4):639-51. PubMed ID: 25492659
[TBL] [Abstract][Full Text] [Related]
5. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo FG; Lin T; Remington JS
J Infect Dis; 1993 Feb; 167(2):494-7. PubMed ID: 8421189
[TBL] [Abstract][Full Text] [Related]
6. Rifabutin is active in murine models of toxoplasmosis.
Araujo FG; Slifer T; Remington JS
Antimicrob Agents Chemother; 1994 Mar; 38(3):570-5. PubMed ID: 8203856
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.
Moshkani SK; Dalimi A
Vet Res Commun; 2000 Apr; 24(3):169-77. PubMed ID: 10836275
[TBL] [Abstract][Full Text] [Related]
8. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo FG; Suzuki Y; Remington JS
Eur J Clin Microbiol Infect Dis; 1996 May; 15(5):394-7. PubMed ID: 8793398
[TBL] [Abstract][Full Text] [Related]
9. Combined effect of atovaquone and pyrrolidine dithiocarbamate in the treatment of acute murine toxoplasmosis.
Djurković-Djaković O; Nikolić A; Bobić B; Klun I
Chemotherapy; 2004 Jun; 50(3):155-6. PubMed ID: 15272229
[No Abstract] [Full Text] [Related]
10. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.
Romand S; Della Bruna C; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 Sep; 40(9):2015-20. PubMed ID: 8878573
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii.
Djurković-Djaković O; Milenković V; Nikolić A; Bobić B; Grujić J
J Antimicrob Chemother; 2002 Dec; 50(6):981-7. PubMed ID: 12461021
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis.
Sordet F; Aumjaud Y; Fessi H; Derouin F
Parasite; 1998 Sep; 5(3):223-9. PubMed ID: 9772721
[TBL] [Abstract][Full Text] [Related]
13. Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis.
Khan AA; Slifer T; Araujo FG; Polzer RJ; Remington JS
Antimicrob Agents Chemother; 1997 May; 41(5):893-7. PubMed ID: 9145840
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic efficacy of recombinant IL-12, clindamycin alone or in combination against experimental reactivated toxoplasmosis.
Tawfeek GM; Oteifa NM; Mustafa MA
J Egypt Soc Parasitol; 2001 Dec; 31(3):853-66. PubMed ID: 11775111
[TBL] [Abstract][Full Text] [Related]
15. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.
Dunay IR; Heimesaat MM; Bushrab FN; Müller RH; Stocker H; Arasteh K; Kurowski M; Fitzner R; Borner K; Liesenfeld O
Antimicrob Agents Chemother; 2004 Dec; 48(12):4848-54. PubMed ID: 15561866
[TBL] [Abstract][Full Text] [Related]
16. Depletion of CD4+ T cells but not inhibition of the protective activity of IFN-gamma prevents cure of toxoplasmosis mediated by drug therapy in mice.
Araujo FG
J Immunol; 1992 Nov; 149(9):3003-7. PubMed ID: 1357033
[TBL] [Abstract][Full Text] [Related]
17. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.
Schöler N; Krause K; Kayser O; Müller RH; Borner K; Hahn H; Liesenfeld O
Antimicrob Agents Chemother; 2001 Jun; 45(6):1771-9. PubMed ID: 11353624
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
Alves CF; Vitor RW
Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831
[TBL] [Abstract][Full Text] [Related]
19. [Effects of azithromycin and Chlorella vulgaris treatment on certain cytokine values and NK cell activity in an acute murine toxoplasmosis model].
Çelik Payçu DG; Büyükbaba Boral Ö
Mikrobiyol Bul; 2017 Jan; 51(1):52-61. PubMed ID: 28283010
[TBL] [Abstract][Full Text] [Related]
20. Atovaquone and azithromycin for the treatment of babesiosis.
Krause PJ; Lepore T; Sikand VK; Gadbaw J; Burke G; Telford SR; Brassard P; Pearl D; Azlanzadeh J; Christianson D; McGrath D; Spielman A
N Engl J Med; 2000 Nov; 343(20):1454-8. PubMed ID: 11078770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
